On November 19, 2019 Oncopeptides reported Interim result of Q3 2019 (Press release, Oncopeptides, NOV 19, 2019, View Source [SID1234551456]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Financial overview July 1 – September 30, 2019
Net sales amounted to SEK 0.0 M (0.0)
Loss for the period was SEK 189.8 M (loss: 94.0)
Loss per share, before and after dilution, was SEK 3.53 (loss: 2.14)
On September 30 cash and cash equivalents amounted to SEK 1,122.3 M (488.9)
Significant events during the period July 1 – September 30, 2019
In late August it was announced that Klaas Bakker, MD, PhD, was appointed as Chief Medical Officer and assumed his duties in early November
In mid-September new interim data in RRMM patients with extramedullary disease (EMD) from the pivotal Phase 2 HORIZON trial were presented at the International Myeloma Workshop
At the end of September, it was announced that the patient recruitment in the pivotal Phase 2 HORIZON trial had been completed
Financial overview of the group
1) Earlier periods have been adjusted to reflect correction of errors, see note 7.
Conference call for investors, analysts and the media
The Interim Report Q3 2019 and an operational update will be presented by CEO Jakob Lindberg and members of Oncopeptides management team, Tuesday November 19, 2019 at 13:30 (CET). The conference call will also be streamed via a link on the website: www.oncopeptides.com.
Phone numbers for participants from:
Sweden: +46 8 505 583 59
Europe: +44 3333 009 034
USA: +1 833 823 05 89
Financial calendar
Year-end Report 2019: February 20, 2020
Interim Report Q1, 2020: May 26, 2020
Annual General Meeting May 26, 2020